Nithya Ramnath

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. pmc A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer
    N Ramnath
    Division of Medical Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA
    Cancer Chemother Pharmacol 71:1173-82. 2013
  2. pmc Characterization of vitamin D receptor (VDR) in lung adenocarcinoma
    So Hee Kim
    Division of Medical Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, USA
    Lung Cancer 77:265-71. 2012
  3. pmc CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma
    Guoan Chen
    Section of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 17:817-26. 2011
  4. doi request reprint Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York City, New York, USA
    J Thorac Oncol 6:1117-20. 2011
  5. pmc Changes in global function and regional ventilation and perfusion on SPECT during the course of radiotherapy in patients with non-small-cell lung cancer
    Shuanghu Tiger Yuan
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA
    Int J Radiat Oncol Biol Phys 82:e631-8. 2012
  6. doi request reprint Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer
    Bryan J Schneider
    Department of Internal Medicine, Weill Cornell Medical College, New York, NY, USA
    Clin Lung Cancer 11:223-7. 2010
  7. pmc Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis
    Guoan Chen
    Department of Surgery, University of Michigan Medical School, Ann Arbor, Michigan 48109 5942, USA
    J Thorac Oncol 6:1481-7. 2011
  8. ncbi request reprint The vitamin D/CYP24A1 story in cancer
    Amanda N King
    Department of Medicine, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Anticancer Agents Med Chem 10:213-24. 2010
  9. doi request reprint Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
    Nithya Ramnath
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Chest 143:e314S-40S. 2013
  10. pmc Semiquantification and classification of local pulmonary function by V/Q single photon emission computed tomography in patients with non-small cell lung cancer: potential indication for radiotherapy planning
    Shuanghu Tiger Yuan
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA
    J Thorac Oncol 6:71-8. 2011

Collaborators

Detail Information

Publications11

  1. pmc A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer
    N Ramnath
    Division of Medical Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA
    Cancer Chemother Pharmacol 71:1173-82. 2013
    ..The goals of this phase I/II study were to determine the recommended phase II dose (RP2D) of 1,25-D3 with cisplatin and docetaxel and its efficacy in metastatic non-small-cell lung cancer...
  2. pmc Characterization of vitamin D receptor (VDR) in lung adenocarcinoma
    So Hee Kim
    Division of Medical Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, USA
    Lung Cancer 77:265-71. 2012
    ..In the present study, we characterized VDR expression in lung adenocarcinoma (AC)...
  3. pmc CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma
    Guoan Chen
    Section of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 17:817-26. 2011
    ..The purpose of our study was to assess CYP24A1 as a prognostic marker and to study its relevance to antiproliferative activity of 1,25-D(3) in lung AC cells...
  4. doi request reprint Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York City, New York, USA
    J Thorac Oncol 6:1117-20. 2011
    ..The prognosis for patients with extensive-stage small cell lung cancer remains poor. This trial was designed to evaluate the efficacy and toxicity of maintenance sunitinib after platinum-etoposide chemotherapy...
  5. pmc Changes in global function and regional ventilation and perfusion on SPECT during the course of radiotherapy in patients with non-small-cell lung cancer
    Shuanghu Tiger Yuan
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA
    Int J Radiat Oncol Biol Phys 82:e631-8. 2012
    ....
  6. doi request reprint Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer
    Bryan J Schneider
    Department of Internal Medicine, Weill Cornell Medical College, New York, NY, USA
    Clin Lung Cancer 11:223-7. 2010
    ..This trial was designed to evaluate irinotecan/cisplatin plus maintenance imatinib in patients with c-Kit-positive disease (the transmembrane receptor c-Kit is the product of the c-KIT protooncogene)...
  7. pmc Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis
    Guoan Chen
    Department of Surgery, University of Michigan Medical School, Ann Arbor, Michigan 48109 5942, USA
    J Thorac Oncol 6:1481-7. 2011
    ..This prospective study aimed to develop a robust and clinically applicable method to identify patients with high-risk early-stage lung cancer and then to validate this method for use in future translational studies...
  8. ncbi request reprint The vitamin D/CYP24A1 story in cancer
    Amanda N King
    Department of Medicine, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Anticancer Agents Med Chem 10:213-24. 2010
    ..The following review summarizes the available literature on CYP24A1 as it relates to 1,25(OH)(2)D(3) in cancer and outlines potential ways to inhibit CYP24A1 in an effort to improve the efficacy of exogenous 1,25(OH)(2)D(3)...
  9. doi request reprint Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
    Nithya Ramnath
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Chest 143:e314S-40S. 2013
    ..This review updates the published clinical trials since the last American College of Chest Physicians guidelines to make treatment recommendations for this controversial subset of patients...
  10. pmc Semiquantification and classification of local pulmonary function by V/Q single photon emission computed tomography in patients with non-small cell lung cancer: potential indication for radiotherapy planning
    Shuanghu Tiger Yuan
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA
    J Thorac Oncol 6:71-8. 2011
    ....
  11. doi request reprint Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience
    Sikander Ailawadhi
    Department of Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Mich 48109, USA
    Oncology 76:85-90. 2009
    ..Erlotinib is approved as treatment for metastatic non-small-cell lung cancer (NSCLC), following failure of initial therapy. Studies to define patients that derive maximal benefit from erlotinib have not dictated current practice...